Page 5 - Kernal Biologics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Here, in our final post, we provide an analysis of the current landscape and offer conclusions. Moderna, BioNTech and CureVac –Leading Pioneers The three largest and best-positioned players in the mRNA space are currently Moderna, BioNTech and CureVac, each having very large patent estates, 11-figure market caps, double-digit candidates in their pipelines, years of development work and accumulated know-how under their belts, and key licenses and other strategic alliances in place for the manufacture, development, and commercialization of mRNA-based products. Moderna and BioNTech (with Pfizer) have each broken through certain regulatory barriers for mRNA with the approvals to commercialize their respective COVID-19 vaccine products, and CureVac is apparently not far behind with a COVID-19 vaccine of its own in Phase 3 clinical trials.

San diegoUnited statesBenjamin grahamStephane bancelNovartis glaxosmithkline bayerAlbert bourlaGenentech sanofiGenevant sciencesMerck kgaIntegra lifesciencesi ltdMerck kgaaKernal biologics incCompetitive landscapeCurevac carrier moleculeOrnithine transcarbamylase deficiencyLike translate